Therefore, this study is the first to target MRTK, a rare tumour, in combination with the MMP inhibitor doxycycline, aiming to determine whether EMT, as well as the differential expression of MMP2 and MMP9, exists in MRTK. This evidence concerns the gene MMP9 and neoplasm.